123 related articles for article (PubMed ID: 26424546)
1. CD4/CD8 ratio: an emerging biomarker for HIV.
Serrano-Villar S; Deeks SG
Lancet HIV; 2015 Mar; 2(3):e76-7. PubMed ID: 26424546
[No Abstract] [Full Text] [Related]
2. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.
Mussini C; Lorenzini P; Cozzi-Lepri A; Lapadula G; Marchetti G; Nicastri E; Cingolani A; Lichtner M; Antinori A; Gori A; d'Arminio Monforte A;
Lancet HIV; 2015 Mar; 2(3):e98-106. PubMed ID: 26424550
[TBL] [Abstract][Full Text] [Related]
3. Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.
Abbas UL; Mellors JW
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13377-8. PubMed ID: 12370421
[No Abstract] [Full Text] [Related]
4. In HIV-infected patients, some differential alterations of CD4 and CD8 T cell homeostasis may not be restored by ≥ 7 years of highly active antiretroviral therapy, in spite of good CD4 T cell repopulation.
Bordoni V; Agrati C; Rinaldi A; Viola D; De Simone G; Gioia C; Martini F
J Antimicrob Chemother; 2012 Jul; 67(7):1802-4. PubMed ID: 22461310
[No Abstract] [Full Text] [Related]
5. Naive and memory CD4⁺ T cells in HIV eradication and immunization.
Zhang J; Poznansky M; Crumpacker C
J Infect Dis; 2012 Aug; 206(4):617-8; author reply 618. PubMed ID: 22696498
[No Abstract] [Full Text] [Related]
6. The search for data on when to start treatment for HIV infection.
Hughes MD; Ribaudo HR
J Infect Dis; 2008 Apr; 197(8):1084-6. PubMed ID: 18462158
[No Abstract] [Full Text] [Related]
7. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study.
Mussini C; Lorenzini P; Cozzi-Lepri A; Marchetti G; Rusconi S; Gori A; Nozza S; Lichtner M; Antinori A; Cossarizza A; d'Arminio Monforte A;
BMC Med; 2018 May; 16(1):79. PubMed ID: 29807541
[TBL] [Abstract][Full Text] [Related]
8. [Japanese guidelines for HIV infection].
Ota Y
Nihon Rinsho; 2003 Feb; 61 Suppl 2():670-6. PubMed ID: 12722299
[No Abstract] [Full Text] [Related]
9. Strategies of HIV management--when to start.
Youle M
AIDS; 2002; 16 Suppl 4():S145-9. PubMed ID: 12699011
[No Abstract] [Full Text] [Related]
10. HIV neutralizing antibody titer during structured treatment interruption of highly active antiretroviral therapy.
Nicastri E; Dori L; Buonomini AR; Tommasi C; De Nardo P; Bellagamba R; Corpolongo A; Montano M; Sordillo P; Volpi A; Sarmati L; Andreoni M
AIDS; 2012 Jul; 26(11):1451-2. PubMed ID: 22767346
[No Abstract] [Full Text] [Related]
11. What do the studies show about STIs in the chronically HIV-1 infected patient?
Wilcox RD
HIV Clin; 2006; 18(2):1-3. PubMed ID: 16941772
[No Abstract] [Full Text] [Related]
12. Are short interruptions safe?
Nagy GS
AIDS Clin Care; 2002 May; 14(5):47. PubMed ID: 12004880
[No Abstract] [Full Text] [Related]
13. Effect of IL-2 therapy on CD8+ cell noncytotoxic anti-HIV response during primary HIV-1 infection.
Martinez-Mariño B; Ashlock BM; Shiboski S; Hecht FM; Levy JA
J Clin Immunol; 2004 Mar; 24(2):135-44. PubMed ID: 15024180
[TBL] [Abstract][Full Text] [Related]
14. Risks higher in GTI at higher CD4 threshold.
Thaczuk D
IAPAC Mon; 2007 Feb; 13(2):39-40. PubMed ID: 17948600
[No Abstract] [Full Text] [Related]
15. Differential alterations of the CD4 and CD8 T cell subsets in HIV-infected patients on highly active antiretroviral therapy with low CD4 T cell restoration.
Méndez-Lagares G; García-Pergañeda A; del Mar del Pozo-Balado M; Genebat M; Ruiz-Mateos E; García García M; Muñoz-Fernández MÁ; Pacheco YM; Leal M
J Antimicrob Chemother; 2012 May; 67(5):1228-37. PubMed ID: 22287235
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.
Torti C; Prosperi M; Motta D; Digiambenedetto S; Maggiolo F; Paraninfo G; Ripamonti D; Cologni G; Fabbiani M; Caputo SL; Sighinolfi L; Ladisa N; El-Hamad I; Quiros-Roldan E; Frank I
Clin Microbiol Infect; 2012 May; 18(5):449-58. PubMed ID: 21919996
[TBL] [Abstract][Full Text] [Related]
17. The START Trial: Definitive Evidence to Treat All HIV-Positive Persons Regardless of CD4 Counts.
Tabernilla A; Poveda E
AIDS Rev; 2015; 17(3):187. PubMed ID: 26450809
[No Abstract] [Full Text] [Related]
18. Antiretroviral Regimens and CD4/CD8 Ratio Normalization in HIV-Infected Patients during the Initial Year of Treatment: A Cohort Study.
De Salvador-Guillouët F; Sakarovitch C; Durant J; Risso K; Demonchy E; Roger PM; Fontas E
PLoS One; 2015; 10(10):e0140519. PubMed ID: 26485149
[TBL] [Abstract][Full Text] [Related]
19. Intermittent therapy for the treatment of chronic HIV infection.
Ananworanich J; Hirschel B
AIDS; 2007 Jan; 21(2):123-34. PubMed ID: 17197802
[No Abstract] [Full Text] [Related]
20. Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery.
Massanella M; Negredo E; Puig J; Puertas MC; Buzón MJ; Pérez-Álvarez N; Carrillo J; Clotet B; Martínez-Picado J; Blanco J
AIDS; 2012 Nov; 26(18):2285-93. PubMed ID: 23018435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
